# EDGAR Filing Document

**Accession Number:** 0001619856
**File Stem:** 0001619856-25-000047
**Filing Date:** 2025-6
**Character Count:** 7436
**Document Hash:** 45d0941f077cb8fff2fafa8d0a6a070e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001619856-25-000047.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001619856-25-000047

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250612

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Caribou Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001619856
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 453728228
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40631
- **FILM NUMBER:** 251046334

**BUSINESS ADDRESS:**
- **STREET 1:** 2929 7TH STREET, SUITE 105
- **CITY:** BERKELEY
- **STATE:** CA
- **ZIP:** 94710
- **BUSINESS PHONE:** 510-982-6030

**MAIL ADDRESS:**
- **STREET 1:** 2929 7TH STREET, SUITE 105
- **CITY:** BERKELEY
- **STATE:** CA
- **ZIP:** 94710

?xml version='1.0' encoding='ASCII'? crbu-20250612

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

________________________________________

**FORM 8-K**

________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 12, 2025**

________________________________________

**Caribou Biosciences, Inc.**

**(Exact name of Registrant as Specified in Its Charter)**

________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40631** | **45-3728228** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| **2929 7th Street, Suite 105**<br>**Berkeley, California** | | **94710** |
| **(Address of Principal Executive Offices)** | | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (510) 982-6030**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | CRBU | NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 12, 2025, Caribou Biosciences, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). The final results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth below. A more detailed description of each proposal is set forth in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 25, 2025.

**Proposal 1 - Election of Two Class I Directors**

Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2028 annual meeting of stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation, or removal.

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| Scott Braunstein, M.D. | 40,215,339 | 1,952,924 | 25,753,089 |
| Ran Zheng, M.S. | 30,392,577 | 11,775,686 | 25,753,089 |

---

**Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm**

The stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Abstain** | **Broker Non-Votes** |
| 66,475,457 | 1,063,333 | 382,562 | 0 |

---

**Proposal 3 - Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split of the Company's Common Stock at a Ratio from any Whole Number Between 1-for-5 and 1-for-50, Inclusive, as Determined by the Company's Board of Directors in its Discretion, Subject to the Board's Authority to Abandon such Amendment in its Discretion.** 

The stockholders approved the above-referenced amendment to the Company's amended and restated certificate of incorporation by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Abstain** | **Broker Non-Votes** |
| 59,816,707 | 7,801,912 | 302,733 | 0 |

---

**Proposal 4 - Approval of the Adjournment of the 2025 Annual Meeting to a Later Date or Dates, if Necessary, to Permit Further Solicitation and Voting of Proxies in the Event There are not Sufficient Votes in Favor of any of Proposals 1-3 or if There are not Sufficient Shares Present to Establish a Quorum.** 

The stockholders approved the adjournment of the 2025 annual meeting, if necessary, by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Abstain** | **Broker Non-Votes** |
| 47,879,959 | 19,670,987 | 370,406 | 0 |

---

Adjournment of the 2025 annual meeting was not necessary because there was a quorum and there were sufficient votes to elect all director nominees and in favor of proposals 2 and 3.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | Caribou Biosciences, Inc. |
| Date: | June 13, 2025 | By: | /s/ Rachel E. Haurwitz |
|  |  |  | Rachel E. Haurwitz, Ph.D.<br>President and Chief Executive Officer |

---